Supplementary Table S1 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
Year: 2024
Type: supplementary-materials
Abstract: PROSeq analysis of gene expression changes following treatment of MCF7 and CAMA-1 cells with ER-alpha ligands.
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4392383477